Developing and characterizing a mouse model of hepatotoxicity using oral pyrrolizidine alkaloid (monocrotaline) administration, with potentiation of the liver injury by co-administration of LPS

Natural Product Communications

Volumn 5, Issue 9, 2010, Pages 1457-1462

  Abdel Bakky, Mohamed Sadek ^a   Hammad, Mohamed A ^a,b   Walker, Larry A ^a,b   Ashfaq, Mohammad K ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

ALT; Hepatotoxicity; IL 1 ; Lipopolysaccharide; Monocrotaline; Pyrrolizidine alkaloids

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MONOCROTALINE; PYRROLIZIDINE ALKALOID; TRANSFORMING GROWTH FACTOR BETA; ALANINE AMINOTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL MODEL; HISTOPATHOLOGY; IN VIVO STUDY; LIVER INJURY; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; ANIMAL; BLOOD; DRUG EFFECTS; LIVER; PATHOLOGY; TOXICITY;

ANIMALIA; MUS;

ALANINE TRANSAMINASE; ANIMALS; C-REACTIVE PROTEIN; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MODELS, ANIMAL; MONOCROTALINE; TRANSFORMING GROWTH FACTOR BETA;

EID: 77956700030     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x1000500922     Document Type: Article

References (28)

1. (a) Copple BL, Ganey PE, Roth RA. (2003) Liver inflammation during monocrotaline hepatotoxicity. Toxicology, 190, 155-169;
2. (b) Mingatto FE, Dorta DJ, dos Santos AB, Carvalho I, da Silva CH, da Silva VB, Uyemura SA, dos Santos AC, Curti C. (2007) Dehydromonocrotaline inhibits mitochondrial complex I. A potential mechanism accounting for hepatotoxicity of monocrotaline. Toxicon, 50, 724-730;
3. (c) Maddox JF, Amuzie CJ, Li M, Newport SW, Sparkenbaugh E, Cuff CF, Pestka JJ, Cantor GH, Roth RA, Ganey PE. (2010) Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. Journal of Toxicology and Environmental Health, 73, 58-73;
4. (d) Zimmerman, H.J. (1993) Hepatotoxicity. Disease-A-Month, 39, 675-787;
5. (e) Zimmerman, H.J. (2000) Drug-induced liver disease. Clinical Liver Disease, 4, 73-96, vi.
6. Copple BL, Rondelli CM, Maddox JF, Hoglen NC, Ganey PE, Roth RA. (2004) Modes of cell death in rat liver after monocrotaline exposure. Toxicological Sciences, 77, 172-182;
7. (g) Imaeda A., Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, Flavell R., Mehal WZ. (2009) Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. Journal of Clinical Investigation, 119, 305-314;
8. Tilg H. (1993) The role of cytokines in the pathophysiology of chronic liver diseases. International Journal of Clinical Laboratory Research, 23, 179-185.
9. Calabro P, Chang DW, Willerson JT, Yeh ET. (2005) Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. Jounal of American College of Cardiology, 46,1112-1113. (Pubitemid 41316523)
10. Sasaki K, Fujita I, Hamasaki Y, Miyazaki S. (2002) Differentiating between bacterial and viral infection by measuring both C-reactive protein and 2′-5′'-oligoadenylate synthetase as inflammatory markers. Journal of Infection and Chemotherapy, 8, 76-80. (Pubitemid 34456584)
11. Turato C, Calabrese F, Biasiolo A, Quarta S, Ruvoletto M, Tono N, Paccagnella D, Fassina G, Merkel C, Harrison TJ, Gatta A, Pontisso P. (2010) SERPINB3 modulates TGF-beta expression in chronic liver disease. Laboratory Investigation, doi:10.1038/labinvest.2010.55; published online 8 March 2010;
12. (b) Yee SB, Hanumegowda UM, Copple BL, Shibuya M, Ganey PE, Roth RA. (2003) Endothelial cell injury and coagulation system activation during synergistic hepatotoxicity from monocrotaline and bacterial lipopolysaccharide coexposure. Toxicological Sciences, 74, 203-14;
13. (c) Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. (2005) C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. American Journal of Pathology, 167, 1139-1148.
14. (a) Galve-de RB, Wiktorowicz K, Kushner I, Dayer JM. (1993) C-reactive protein increases production of IL-1 alpha, IL-1 beta, and TNF-alpha, and expression of mRNA by human alveolar macrophages. Journal of Leukocyte Biology, 53, 439-445; (Pubitemid 23159886)
15. (b) Du Clos TW. (2000) Function of C-reactive protein. Annals of Medicine, 3, 274-278;
16. (c) Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 51, 1596-1600; (Pubitemid 34826630)
17. (d) Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G, Gunsar F, Batur Y. (2009) Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC. Gastroenterology, 9, 16-20;
18. (e) Aronson D, Bartha P, Zinder O, Kerner A, Shitman E, Markiewicz W, Brook GJ, Levy Y. (2004) Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabetic Medicine, 21, 39-44; (Pubitemid 38168027)
19. (f) James LP, Mayeux PR, Hinson JA. (2003) Acetaminophen-induced hepatotoxicity. Drug Metabolism and Disposition, 31, 1499-1506.
20. (a) Nystrom T. (2007) C-reactive protein: a marker or a player? Clinical Science (London), 113, 79-81;
21. (b) Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum Buschenfelde KH, Blessing M. (1999) TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. American Journal of Physiology, 276, G1059-G1068.
22. (a) Luo DD, Fielding C, Phillips A, Fraser D. (2009) Interleukin-1 beta regulates proximal tubular cell transforming growth factor beta-1 signalling. Nephrology Dialysis Transplantation, 24, 2655-2665;
23. (b) Xu D, Wu Y, Liao ZX, Wang H. (2007) Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats. Pharmacological Research, 55, 280-286. (Pubitemid 46518158)
24. (a) Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. (2005) Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcoholism. Clinical and Experimental Research, 29, 121S-131S;
25. (b) Kao YH, Jawan B, Goto S, Pan MC, Lin YC, Sun CK, Hsu LW, Tai MH, Cheng YF, Nakano T, Wang CS, Huang CJ, Chen CL (2009) Serum factors potentiate hypoxia-induced hepatotoxicity in vitro through increasing transforming growth factor-beta1 activation and release. Cytokine, 47, 11-22.
26. (a) Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, Manigrasso MR, Basili S, Davi G. (2003) Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. Journal of Clinical Endocrinology and Metabolism, 88, 5321-5326; (Pubitemid 37452734)
27. (b) Taylor AW, Ku NO, Mortensen RF. (1990) Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta. The Journal of Immunology, 145, 2507-2513;
28. (c) McGee DW, Beagley KW, Aicher WK, McGhee JR. (1993) Transforming growth factor-beta and IL-1 beta act in synergy to enhance IL-6 secretion by the intestinal epithelial cell line, IEC-6. The Journal of Immunology, 151, 970-978.